Is Theravance Biopharma, Inc. (NASDAQ:TBPH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Theravance Biopharma, Inc. at current levels.
A two-product binary with a covered downside: YUPELRI throws off cash while ampreloxetine's MSA readout could double the company.
Where TBPH is headed
Theravance in mid-2027 looks almost nothing like the company the market is pricing today. YUPELRI, the nebulized LAMA for COPD partnered with Viatris, is doing the unglamorous work of paying the bills, growing mid-teens off a hospital and home-nebulizer base that's stickier than inhaler bulls give it credit for. That single product is enough to cover OpEx, fund the pipeline, and let management keep running the buyback that has already taken the share count down meaningfully since 2022. The Compass Score of 77 is doing real work here: this is a profitable, FCF-positive biotech trading at 7x trailing earnings with net cash. That's not a normal biotech setup.
Read the full Compass Direction on TBPH
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $16.37).
See the full TBPH analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Theravance Biopharma, Inc. at current levels. A two-product binary with a covered downside: YUPELRI throws off cash while ampreloxetine's MSA readout could double the company.
What is TBPH's Compass Score?
Theravance Biopharma, Inc. scores 77/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TBPH?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TBPH page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.